Table 5 All-cause adverse events
| Â | Placebo N= 248 | Pregabalin N= 250 |
|---|---|---|
Adverse events | 175 (70.6)a | 225 (90.0) |
Serious adverse events | 1 (0.4) | 3 (1.2) |
Severe adverse events | 0 | 2 (0.8) |
Discontinuations due to adverse events | 9 (3.6) | 24 (9.6) |
Dose reductions/temporary discontinuations due to adverse events | 11 (4.4) | 30 (12.0) |
Frequent adverse eventsb | Â | Â |
   Somnolence | 45 (18.1) | 116 (46.4) |
   Dizziness | 15 (6.0) | 74 (29.6) |
   Nasopharyngitis | 45 (18.1) | 45 (18.0) |
   Increased weight | 9 (3.6) | 39 (15.6) |
   Constipation | 17 (6.9) | 36 (14.4) |
   Feeling abnormal | 3 (1.2) | 20 (8.0) |
   Peripheral edema | 3 (1.2) | 18 (7.2) |
   Headache | 15 (6.0) | 15 (6.0) |
   Vision blurred | 3 (1.2) | 13 (5.2) |